Coronavirus COVID-19 Outbreak – What's New

Updated: Sunday, March 29, 2020 13:05 ET

Using the Relief Central App?

What’s New Here

What’s New Elsewhere on Site

Share this page

Share by email Share by Facebook Share by Twitter

COVID-19 Cases

Around the Globe

  • Cases of COVID-19 reported daily by WHO have reached more than 570,000 – an increase of more than 62,000 since the last report.[1]
  • Velocity of new reported cases remains highest in the United States followed by Spain, Germany, Italy, and France.[1]
  • See Comparison of Epidemic Curves by Country for details.
COVID-19 Outbreak Map by Johns Hopkins CSSE – Updated Hourly
Coronavirus 2019 COVID-19 Outbreak Map

Click one of the links below to see the latest.
Desktop | Mobile
Source: Johns Hopkins Center for Systems Science and Engineering (CSSE).[2]

Total and New COVID-19 Cases — Updated Daily by WHO

Confirmed Cases

Deaths

Total

New

Total

New

United States

85,228

16,894

1,243

252

Spain

64,059

7,871

4,858

769

Germany

48,582

6,294

325

72

Italy

86,498

5,959

9,136

971

France

32,542

3,756

1,992

297

Iran

32,332

2,926

2,378

144

United Kingdom

14,547

2,885

759

181

China

82,230

152

3,301

3

South Korea

9,478

146

144

5

Japan

1,499

112

49

3

Other Countries (159)

114,683

15,519

2,309

462

TOTAL

571,678

62,514

26,494

3,159

World Health Organization as of March 28, 2020.[1]

Note: WHO statistics are reported daily. See other sources for hour-by-hour updates.

Statistics may differ from other reporting agencies.

In the United States

  • As of March 27 at 07:00 ET [3]
    • Cases in the US have surpasses those in all other countries including China. Cases have reached nearly 124,000 in all 50 states, with the most cases in New York (53k), New Jersey (11k), California (5.5k), Michigan (4.6k), Washington state (4.3k), and Massachusetts (4.2k).
    • More than 2,100 deaths have been reported – with the most in New York (782), Washington State (191), Louisiana (137), New Jersey (140), California (121), Michigan (111), Georgia (79), Florida (56) and Illinois (50).
  • See the New York Times for hour-by-hour updates.

Public Health

News

  • Three pillars remain the focus: testing and isolation of positive cases; social distancing; and restricting travel to/from hot spots.
  • CDC issued a travel advisory for New York, New Jersey and Connecticut asking residents to curtail non-essential domestic travel for the next 14 days.[4]
  • NEJM article Epidemiology of COVID-19 in a Long-Term Care Facility in Washington State highlights the importance of protecting long-term care facilities.[5]
  • In March 27 report, WHO continues to recommend droplet and contact precautions for those people caring for COVID-19 patients and contact and airborne precautions for circumstances and settings in which aerosol generating procedures are performed.[6]
  • Countries and cities continue to institute stay-at-home orders and ban gatherings of more than two people.

Resources

Medical

Clinical Care

  • COVID-19 Diagnosis & Treatment – from the Johns Hopkins Antibiotic (ABX) Guide powered by Unbound Medicine
    • COVID-19 testing in the US:
      • Since the FDA has allowed bypass of federal approval, more assays are becoming available.
      • Many tests currently offered, however, have not been validated clinically. FDA has warned not to use these to implicate authentic infection, protective immunity or to rule out infection.
    • Mortality rates by age in the US added from data published in MMWR journal.
    • Journal article reports decreased SARS-CoV-2 shedding in 6 patients in a post-hoc analysis of a non-RCT trial involving 36 patients when hydroxychloroquine was combined with azithromycin.
    • Preliminary evidence in humans and SARS-CoV-2-infected rhesus macaques suggest that reinfection does not occur.

Drugs

  • No drugs have yet been approved for the specific treatment of COVID-19 patients by the US Food and Drug Administration (FDA).
  • Treatments under study:
    • Convalescent plasma: in an uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in clinical status.[7] Other Convalescent Plasma Clinical Trials are underway.
    • Hydroxychloroquine and chloroquine inhibit growth of SARS-CoV-2 in vitro, but no clinical trials have demonstrated conclusively their effectiveness in humans. See Chloroquine / Hydroxychloroquine in Coronavirus COVID-19.
    • Remdesivir (Gilead), an investigational IV drug with broad antiviral activity, is being investigated in multiple clinical trials. In the US, it can be obtained as part of participation in a clinical trial.
    • Lopinavir-ritonavir (AbbVie; Kaletra, Aluvia) showed "no benefit" in hospitalized adult patients with severe COVID-19 according to a study published in the New England of Journal of Medicine.[8] Many other trials are underway, see Lopinavir-Ritonavir Clinical Trials.
    • Tocilizumab (Genentech; Actemra) a monoclonal antibody which blocks the IL-6 signalling pathway is being investigated in a number of Tocilizumab Clinical Trials.
    • Favipiravir (Toyama Chemical; Avigan), an antiviral drug under study alone and in combination with tocilizumab, see Favipiravir Clinical Trials.

Vaccines

Resources

For the Public

Feedback

Your feedback is appreciated!

Share this page

Share by email Share by Facebook Share by Twitter

References

  1. Coronavirus Disease 2019 (COVID-19) Situation Reports. World Health Organization. [https://www.who.int…]
  2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020.  [PMID:32087114]
  3. Tracking Every Coronavirus Case in the U.S.: Full Map. New York Times. [https://www.nytimes.com…]
  4. CDC Issues Domestic Travel Advisory for New York, New Jersey, and Connecticut. US Centers for Disease Control and Prevention. [https://www.cdc.gov…]
  5. McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N Engl J Med. 2020.  [PMID:32220208]
  6. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. World Health Organization. 27 March 2020. [https://www.who.int…]
  7. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020.  [PMID:32219428]
  8. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020.  [PMID:32187464]
  9. NIH clinical trial of investigational vaccine for COVID-19 begins: study enrolling Seattle-based healthy adult volunteers [News]. March 16, 2020. [https://www.nih.gov…]
  10. Chen WH, Strych U, Hotez PJ, et al. The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020.  [PMID:32219057]
  11. Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments [News]. March 19, 2020. [https://www.fda.gov…]
  12. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020.  [PMID:32205204]